Sanitas Articles
Sanitas sales hit $16.5M for 1st-half 2006
17 July 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
Sanitas buys Hoechst-Biotika
8 August 2005
Sanitas' 1st-half sales slide down 21%
25 July 2005
Sanitas buys Hoechst Biotika
6 June 2005
Sanitas to build new plant in Lithuania
31 January 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Redundancies at Entokrininiai Preparati
22 November 2004
Sanitas seeking to take over Kalcek's injectables production
6 September 2004
Lithuania: cGMP requirement threatens drugmakers
9 August 2004
Grindeks to off load production at Jelfa
31 May 2004
Grinkdeks may transfer Mildronat production to Poland
26 April 2004
Lithuania's Sanitas names Donatas Jazukevicius as CEO
24 November 2003
Sanitas OKs 2003 sales target
29 September 2003
Sanitas of Lithuania sees sales leap 14%
22 September 2003
SANITAS' losses widen
30 June 2003
Darius Sulnis named chairman of Lithuania's Sanitas
31 March 2003
Bid made for Lithuania's Sanitas
17 March 2003
Latvia's Grindeks to establish drugs holding company?
24 February 2003
Lithuania's Sanitas posts loss in first half
12 August 2002
Swiss health fund in red
13 May 2002
Lithuania drug industry growth
11 February 2002
New DG for Sanitas of Lithuania
15 November 2001
Lithuania's Sanitas reports flat turnover
11 July 2001
Sanitas sales leap 32.4% for 2000
2 February 2001
Sanitas' first-half 2000 profits soar
14 August 2000
Lithuania's Sanitas moves back into profit
3 May 2000
Lithuania's Sanitas first-half profits down
6 August 1999
New markets for Lithuania's Sanitas
11 January 1999
Double-Digit Growth For Sanitas
21 May 1998
Baltic Drug Firms Have Good Prospects, Says Bank
12 January 1998
Lithuania's Sanitas To Package Zantac
10 November 1997
Status Sells Sanitas Stake
18 September 1997
Key Tendencies In the Drug Industry: A Chilean View
15 July 1996
HEALTH INSURANCE IN MOSCOW
24 January 1994
1992 SEES SMALLER COMPANY MERGERS
4 January 1993
HEALTH CARE NEWS FROM ROMANIA
27 January 1992
Showing 1-39 of 39 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
